首页> 美国卫生研究院文献>Canadian Journal of Comparative Medicine >In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus
【2h】

In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus

机译:病毒唑和干扰素-α对犬瘟热病毒的体外抗病毒功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Canine distemper is a highly contagious disease with high incidence and lethality in the canine population. The objective of this study was to evaluate the efficacy of antiviral action with ribavirin (RBV), interferon-alpha (IFNα), and combinations of RBV and IFNα against canine distemper virus (CDV). Vero cells inoculated with CDV were treated with RBV, IFNα, and combinations of these drugs. The efficacy to inhibit viral replication was evaluated by adding the compounds at different times to determine which step of the viral replicative process was affected. Both drugs were effective against CDV in vitro. The IFNα was the most active compound, with an average IC50 (50% inhibitory concentration) value lower than the IC50 of the RBV. Ribavirin (RBV) was more selective than IFNα, however, and neither drug showed extracellular antiviral activity. The combination of RBV and IFNα exhibited antiviral activity for the intra- and extracellular stages of the replicative cycle of CDV, although the intracellular viral inhibition was higher. Both RBV and IFNα showed high antiviral efficacy against CDV, and furthermore, RBV + IFNα combinations have shown greater interference range in viral infectivity. These compounds could potentially be used to treat clinical disease associated with CDV infection.
机译:犬瘟热是一种高度传染性疾病,在犬群中具有很高的发病率和致死性。这项研究的目的是评估利巴韦林(RBV),干扰素-α(IFNα)以及RBV和IFNα组合抗犬瘟热病毒(CDV)的抗病毒作用。接种CDV的Vero细胞用RBV,IFNα和这些药物的组合治疗。通过在不同时间添加化合物来评估抑制病毒复制的功效,以确定病毒复制过程的哪个步骤受到影响。两种药物在体外均对CDV有效。 IFNα是活性最高的化合物,平均IC50(50%抑制浓度)值低于RBV的IC50。利巴韦林(RBV)比IFNα更具选择性,而且两种药物均未显示出细胞外抗病毒活性。 RBV和IFNα的组合对CDV复制周期的细胞内和细胞外阶段均表现出抗病毒活性,尽管细胞内病毒抑制作用更高。 RBV和IFNα均显示出对CDV的高抗病毒效力,此外,RBV +IFNα组合在病毒感染性中显示出更大的干扰范围。这些化合物可潜在地用于治疗与CDV感染相关的临床疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号